Unión Europea - noruego - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Noruega - noruego - Statens legemiddelverk

sandoz - københavn - dasatinib - tablett, filmdrasjert - 70 mg

Noruega - noruego - Statens legemiddelverk

sandoz - københavn - dasatinib - tablett, filmdrasjert - 20 mg

Noruega - noruego - Statens legemiddelverk

sandoz - københavn - dasatinib - tablett, filmdrasjert - 50 mg

Noruega - noruego - Statens legemiddelverk

accord healthcare b.v. - levotyroksinnatrium - tablett - 75 mikrog

Noruega - noruego - Statens legemiddelverk

accord healthcare b.v. - levotyroksinnatrium - tablett - 50 mikrog

Noruega - noruego - Statens legemiddelverk

accord healthcare b.v. - levotyroksinnatrium - tablett - 100 mikrog

Noruega - noruego - Statens legemiddelverk

accord healthcare b.v. - levotyroksinnatrium - tablett - 125 mikrog

Noruega - noruego - Statens legemiddelverk

accord healthcare b.v. - levotyroksinnatrium - tablett - 150 mikrog

Noruega - noruego - Statens legemiddelverk

accord healthcare b.v. - levotyroksinnatrium - tablett - 200 mikrog